Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 and Serplulimab in Advanced Lung Cancer
NCT07253142Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Henlius. Started Feb 2026; status: recruiting.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07253142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253142.